Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

25.74
-1.1550-4.30%
Volume:952.90K
Turnover:24.55M
Market Cap:2.53B
PE:-4.21
High:27.29
Open:26.57
Low:25.22
Close:26.89
52wk High:39.89
52wk Low:18.29
Shares:98.32M
Float Shares:94.49M
Volume Ratio:0.64
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.1099
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-25.45%
PB:-10.72
PE(LYR):-4.41

Loading ...

Ultragenyx Grants 65,886 Restricted Stock Units to 39 New Hires Under Inducement Plan

Reuters
·
Jul 25

Ultragenyx Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 25

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 25

Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Jul 22

Ultragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024

Dow Jones
·
Jul 18

Wedbush Releases a Hold Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Jul 13

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating

MT Newswires Live
·
Jul 13

Ultragenyx Releases 2025 Impact Report Outlining ESG Progress Across Six Pillars

Reuters
·
Jul 08

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors

THOMSON REUTERS
·
Jun 23

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

GlobeNewswire
·
Jun 23

Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs

Reuters
·
Jun 22

Ultragenyx grants 44,409 RSUs to 15 new hires under inducement plan

Reuters
·
Jun 20

Press Release: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Jun 20

Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed?

Simply Wall St.
·
Jun 17

Ultragenyx EVP, Chief Legal Officer Karah Parschauer reports sale of 1,899 common shares worth $46,749.38

Reuters
·
Jun 16

Assessing Ultragenyx Pharmaceutical (RARE) Valuation After UX111 FDA Review Acceptance And Growing GTX-102 Optimism

Simply Wall St.
·
Jun 09

Does Rising GTX-102 Focus Recast Ultragenyx (RARE) as a Concentrated Angelman Syndrome Risk-Reward Story?

Simply Wall St.
·
Jun 07

Ultragenyx Pharmaceutical (RARE) Receives a Buy from J.P. Morgan

TIPRANKS
·
May 23

Ultragenyx grants 17,567 RSUs to 11 new hires under inducement plan

Reuters
·
May 23